Bill > HR3873

This bill, known as the Knock Out Cancer Act, aims to significantly increase funding and research efforts to combat cancer by addressing several key areas. The bill begins by highlighting the severe impact of cancer in the United States, noting that it causes nearly 1 in 4 deaths and has claimed over 15 million American lives since 2000. To address this critical health issue, the legislation proposes to appropriate additional funding to the National Cancer Institute (NCI) for fiscal years 2026-2030, specifically allocating an amount equal to 25 percent of the NCI's 2022 budget, which would be supplemental to existing funding. Additionally, the bill mandates a comprehensive study by the Secretary of Health and Human Services to investigate cancer drug shortages, examining economic factors, supply chain issues, drug development and approval delays, and the availability of generic and biosimilar drugs. The study will culminate in a report to Congress within one year of the bill's enactment, which will include recommendations for addressing these drug shortage challenges. The underlying philosophy of the bill is that increased scientific research and investment can lead to innovations in cancer treatment, earlier detection, and potentially improved survival rates.

Budget and Finance

https://www.congress.gov/bill/119th-congress/house-bill/3873/all-info